These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose. Krízová P; Másová L; Suttnar J; Salaj P; Dyr JE; Homola J; Pecka M J Biomed Mater Res A; 2007 Aug; 82(2):274-80. PubMed ID: 17274026 [TBL] [Abstract][Full Text] [Related]
43. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Seehaus S; Shahzad K; Kashif M; Vinnikov IA; Schiller M; Wang H; Madhusudhan T; Eckstein V; Bierhaus A; Bea F; Blessing E; Weiler H; Frommhold D; Nawroth PP; Isermann B Circulation; 2009 Sep; 120(9):774-84. PubMed ID: 19687358 [TBL] [Abstract][Full Text] [Related]
44. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. van Rooy MJ; Pretorius E Thromb Res; 2015 Mar; 135(3):434-42. PubMed ID: 25601172 [TBL] [Abstract][Full Text] [Related]
45. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. Asero R; Tedeschi A; Coppola R; Griffini S; Paparella P; Riboldi P; Marzano AV; Fanoni D; Cugno M J Allergy Clin Immunol; 2007 Mar; 119(3):705-10. PubMed ID: 17204316 [TBL] [Abstract][Full Text] [Related]
46. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Schmidt R; Bültmann A; Fischel S; Gillitzer A; Cullen P; Walch A; Jost P; Ungerer M; Tolley ND; Lindemann S; Gawaz M; Schömig A; May AE Circ Res; 2008 Feb; 102(3):302-9. PubMed ID: 18048771 [TBL] [Abstract][Full Text] [Related]
48. Short-term treatment of stroke-prone spontaneously hypertensive rats with an AT1 receptor blocker protects against hypertensive end-organ damage by prolonged inhibition of the renin-angiotensin system. Hamaguchi R; Takemori K; Inoue T; Masuno K; Ito H Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1151-5. PubMed ID: 18518883 [TBL] [Abstract][Full Text] [Related]
49. [Migrant thrombophlebitis and blood hypercoagulability caused by probable activation of the Hageman factor-PTA system. (Clinical case)]. Girolami A; Scarpa R; Solimbergo B Cardiol Prat; 1968 Feb; 19(1):17-23. PubMed ID: 5685523 [No Abstract] [Full Text] [Related]
50. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Brambilla M; Camera M; Colnago D; Marenzi G; De Metrio M; Giesen PL; Balduini A; Veglia F; Gertow K; Biglioli P; Tremoli E Arterioscler Thromb Vasc Biol; 2008 May; 28(5):947-53. PubMed ID: 18292391 [TBL] [Abstract][Full Text] [Related]
51. Coagulation cascade. Green D Hemodial Int; 2006 Oct; 10 Suppl 2():S2-4. PubMed ID: 17022746 [TBL] [Abstract][Full Text] [Related]
52. Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Esler M; Eikelis N; Schlaich M; Lambert G; Alvarenga M; Kaye D; El-Osta A; Guo L; Barton D; Pier C; Brenchley C; Dawood T; Jennings G; Lambert E Ann N Y Acad Sci; 2008 Dec; 1148():338-48. PubMed ID: 19120127 [TBL] [Abstract][Full Text] [Related]
53. The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. Ruiz-Ortega M; Esteban V; Egido J Trends Cardiovasc Med; 2007 Jan; 17(1):19-25. PubMed ID: 17210474 [TBL] [Abstract][Full Text] [Related]
54. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development. Vretenbrant K; Ramström S; Bjerke M; Lindahl TL Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509 [TBL] [Abstract][Full Text] [Related]
57. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). Laurel MT; Ratnoff OD; Everson B J Lab Clin Med; 1992 May; 119(5):580-5. PubMed ID: 1374787 [TBL] [Abstract][Full Text] [Related]
58. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. Horký K Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167 [TBL] [Abstract][Full Text] [Related]
59. Redrawing Papez' circuit: a theory about how acute stress becomes chronic and causes disease. Eggers AE Med Hypotheses; 2007; 69(4):852-7. PubMed ID: 17376605 [TBL] [Abstract][Full Text] [Related]
60. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Röther J; Alberts MJ; Touzé E; Mas JL; Hill MD; Michel P; Bhatt DL; Aichner FT; Goto S; Matsumoto M; Ohman EM; Okada Y; Uchiyama S; D'Agostino R; Hirsch AT; Wilson PW; Steg PG; Cerebrovasc Dis; 2008; 25(4):366-74. PubMed ID: 18337635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]